Therapeutic Potential Of The Dipeptidyl Peptidase IV Gene Family
Funder
National Health and Medical Research Council
Funding Amount
$478,067.00
Summary
We will further investigate the therapeutic potential of the Dipeptidyl Peptidase (DP) IV gene family by studying genes identified as probable therapeutic targets for stem cell transplant, anti-inflammatory and cancer therapies. DPIV is an identified target for diabetes therapy. Our research group is internationally recognised as expert in both liver disease pathogenesis and the DPIV gene family.